Advertisement
Document › Details
Illumina, Inc.. (6/28/19). "Press Release: Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US". San Diego, CA.
Region | Switzerland | |
Organisation | Illumina Inc. (Nasdaq: ILMN) | |
Group | Illumina (Group) | |
Organisation 2 | Genoks Genetik Hastaliklar Tani Merkezi | |
Product | BGISeq-500 sequencing system | |
Product 2 | reagents (bio/biochemical) | |
Person | Dadswell, Charles (Illumina 201604 SVP + General Counsel) | |
Person 2 | Ross, Jacquie (Gilead Sciences 202208 Investor Relations before Illumina + Cepheid) | |
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents.
The first complaint was filed against Complete Genomics, Inc. and other BGI entities in the United States District Court for the Northern District of California alleging infringement of U.S. Patent Nos. 7,566,537 and 9,410,200. The second complaint was filed against Latvia MGI Tech SIA in the Federal Patent Court in Switzerland alleging infringement of EP 1 530 578 B1 and EP 1 828 412 B1. A third complaint was filed against BGI’s distributor, Genoks Genetik Hastaliklar Tani Merkezi, in the Istanbul Civil Court for Intellectual and Industrial Rights in Turkey alleging infringement of EP 3 002 289 B1.
The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry. These lawsuits follow related patent suits filed by Illumina against BGI in Germany and Denmark.
“We believe BGI’s infringement is pervasive. Their continued unauthorized infringement requires that we enforce our intellectual property and protect the substantial investments that have been made in our sequencing-by-synthesis chemistry,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Illumina, Inc.
Investors:
Jacquie Ross, CFA
+1-858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com
or
Media – Europe:
Karen Birmingham
+44(0) 7500105665
kbirmingham@illumina.com
Record changed: 2023-06-05 |
Advertisement
More documents for Illumina (Group)
- [1] Delfi Diagnostics, Inc.. (1/5/24). "Press Release: Delfi Diagnostics Appoints Susan Tousi as New Chief Executive Officer". Baltimore, MD & Palo Alto, CA....
- [2] Broken String Biosciences Ltd.. (9/18/23). "Press Release: Broken String Biosciences Closes $15M Series A Funding Round". Cambridge....
- [3] Illumina, Inc.. (9/5/23). "Press Release: Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer". San Diego, CA....
- [4] Illumina, Inc.. (8/28/23). "Press Release: Illumina to Webcast Upcoming Investor Conference". San Diego, CA....
- [5] Illumina, Inc.. (8/17/23). "Press Release: Illumina Expands Genomics Capabilities in India with Opening of Solutions Center". San Diego, CA....
- [6] Illumina, Inc.. (7/18/23). "Press Release: The Alliance for Genomic Discovery Announces Founding Biopharma Members – AbbVie, Amgen, AstraZeneca, Bayer, and Merck". San Diego, CA....
- [7] Illumina, Inc.. (6/11/23). "Press Release: Illumina Announces CEO Transition Plan". San Diego, CA....
- [8] Illumina, Inc.. (10/11/22). "Press Release: Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery". San Diego, CA....
- [9] Illumina, Inc.. (6/28/22). "Press Release: Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health". San Diego, CA....
- [10] Illumina, Inc.. (5/5/22). "Press Release: Illumina and Deerfield Management Partner to Accelerate Drug Development". San Diego, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top